Lundbeck strengthens its R&D organization
The new appointments have been made following the consolidation of Lundbeck's research and development activities into one organization. One result of this consolidation is the creation of a new unit for regulatory product support, patient safety and quality assurance of clinical research. The new unit was established as a consequence of Lundbeck's increased focus on these areas, as the company’s product portfolio has grown and its clinical research activities have increased. Jens Peter Balling has been appointed as vice president of the new unit.
The organization for regulatory development and strategy, which is increasingly important for Lundbeck, has been strengthened at the same time. Iman Barilero, newly appointed as vice president, will be responsible for increasing Lundbeck's strategic efforts to build and maintain constructive cooperation and dialogue with national and international regulatory authorities. She will have particular focus on supporting Lundbeck's many development projects.
"The appointments of Jens Peter Balling and Iman Barilero reflect our efforts to build a strong and competent research and development organization that enables us to continue to deliver results as we invest in the future. The regulatory and safety areas are an increasingly important prerequisite for this. The creation of one new unit and the increased focus on the other gives us a strong position in these areas,” says Anders Gersel Pedersen, Lundbeck's executive vice president of research and development.
The two new vice presidents
Jens Peter Balling joined Lundbeck in 2006 as divisional director of global pharmacovigilance. He has many years of drug safety experience from the Danish pharmaceutical industry, where he previously worked for Novo Nordisk and Nycomed. Jens Peter Balling is now vice president, regulatory affairs, pharmacovigilance & clinical quality assurance.
Iman Barilero joined Lundbeck in 2007, when she started as divisional director of regulatory development, strategy and policy. She has a Ph.D. in pharmacology and a Ph.D. in pharmacy and pharmaceutical chemistry. Iman Barilero has extensive international experience from several years at Hoffmann-La Roche and Johnson & Johnson. She is now vice president, regulatory development strategy & policy.
Contacts
Mads Kronborg, Media Relations Manager Simon Augustesen, Media Relations
Telephone (direct): +45 36 43 28 Telephone (direct): +45 36 43 49 80
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improve the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world, targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's diseases.
Lundbeck was founded by Hans Lundbeck in 1915 in Copenhagen, Denmark, and today employs 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2010, the company's revenue was DKK 14.8 billion (approximately EUR 2.0 billion or USD 2.6 billion). For more information, please visit www.lundbeck.com.
